Enzymes rarely have one job. So, attempts to shut down the enzyme that causes the hallmarks of Alzheimer’s disease often mean side effects, because these therapies prevent the enzyme from carrying out many other functions. A study appearing Feb. 25 in Cell Reports presents a new therapeutic strategy: blocking the most harmful behavior enzyme while allowing it to work normally otherwise. This potential approach now needs to be further developed and tested in pre-clinical trials.